Skip to content
Bipartisan legislation to support research into rare diseases received backing from witnesses and lawmakers during a Feb. 29 hearing of the House Energy and […]
Lawmakers back bipartisan legislation supporting rare disease research Read More »
Even in this challenging market, biotechnology firms are attracting investment and building capital, but they need more than just a great innovation. They also
Biotech investment is scarce, but still available, experts tell CEOs Read More »
Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to
Drug developers and investors need to join AI revolution, panel says Read More »
The science of gene therapies is progressing at a remarkable pace, but if these medicines are going to reach patients, trends in investment and
CEOs say market must keep up with the science of gene therapies Read More »
A proposed World Trade Organization (WTO) IP waiver could have scuttled investment in biotech’s new diabetes drug and already impacts the firm’s decisions about
BIO Board member tells Congress WTO IP waivers hurt innovation Read More »
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year. BIO’s
Congressional action BIO wants to see in 2024 Read More »
After two decades of research and development, Sutro Biopharma is still a few years away from seeking market approval for its first drug, a
Loss of tax incentive for R&D threatens biotech innovation Read More »
The Federal Trade Commission (FTC) challenge of more than 100 patent listings registered with the Food and Drug Administration, mostly for devices used to
The proposed updated European Union General Pharmaceutical Legislation offers some opportunities but also creates some new threats for biotech—and when it becomes law in
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel Read More »
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
